key: cord-0933886-ck6lr14i authors: Popov, Aron Frederik; Berger, R.; Schlensak, Christian; Bongers, Malte N.; Haeberle, Helene; Acharya, Metesh; Lausberg, Henning F. title: Mechanical circulatory support for cardiovascular complications in a young COVID‐19 patient date: 2020-08-02 journal: J Card Surg DOI: 10.1111/jocs.14916 sha: 2eadb60e255bd8711ef5f2bac6846eb7737fc41c doc_id: 933886 cord_uid: ck6lr14i Background: The current coronavirus (COVID‐19) pandemic is associated with severe pulmonary and cardiovascular complications. Case presentation: This report describes a young patient with COVID‐19 without any comorbidity presenting with severe cardiovascular complications, manifesting with pulmonary embolism, embolic stroke, and right heart failure. Conclusion: Management with short‐term mechanical circulatory support, including different cannulation strategies, resulted in a successful outcome despite his critical cardiovascular status. The novel coronavirus (COVID-19) has been identified as the cause of a severe acute respiratory syndrome, accounting for thousands of cases of severe pneumonia, respiratory failure and death globally. 1 Although current management is largely supportive, a minority with cardiocirculatory instability secondary to acute cardiac injury, myocarditis, acute pulmonary embolism, or other complex conditions, 2 require mechanical ventilation or extracorporeal membrane oxygenation. were retrieved ( Figure 1D ). The following day, re-thoracotomy was necessary for evacuation of a mediastinal hematoma, as well as to upgrade from VA-ECMO to veno-arterial-venous ECMO due to ongoing respiratory failure despite VA-ECMO therapy. The patient also developed arterial embolism affecting his left hand, which was treated conservatively in view of adequate anticoagulation with unfractionated heparin while receiving mechanical circulatory support (MCS), and on account of his complex hemodynamic instability. On the second postoperative day, continuous veno-venous hemodialysis was commenced for acute kidney injury. The arterial ECMO cannula was removed 1 week after the initial surgery, following recovery of right heart function, and veno-venous ECMO (VV-ECMO) was maintained for another 10 days. An improvement of lung function and neurological status during VV-ECMO and prone ventilator therapy were observed. The patient was subsequently extubated, and 3 weeks after initial surgery, he was discharged to a rehabilitation unit with right-sided hemiparesis and leg weakness. During his intensive care unit stay, a comprehensive haematology screen did not yield evidence of any underlying hypercoagulable disorder. According to the standard in our centre, the patient was anticoagulated with continuous intravenous heparin with a goal partial thromboplastin time level of 50 to 70 seconds through the ECMO therapy. The use of ECMO has been advocated to sustain respiratory and/or cardiovascular function and might represent the only effective intervention in the difficult circumstances of circulatory instability in COVIDpositive cases. The COVID-BioB Study Group reported that older age, cardiovascular disease, chronic lung disease, hypertension, diabetes, and obesity are associated with worse outcomes. 3 These risk factors, however, were not present in our young patient who nevertheless developed serious cardiovascular complications with pulmonary embolism, embolic stroke, and right heart failure. Indeed, some patients with COVID-19 infection will have a high incidence of venous and arterial thromboembolism within an intensive care setting, which may lead to fatal cardiocirculatory events. 4 Interestingly, it was recently reported that COVID-19 infection is associated with large-vessel stroke in patients younger than 50 years 5 as observed in our patient, which may be attributable to coagulopathy and vascular endothelial dysfunction. 6 ECMO is traditionally utilized as rescue therapy in the most severe cases of refractory cardiorespiratory failure. However, it is associated with significant neurological, vascular, renal and hematological adverse effects, including intracerebral hemorrhage, stroke, limb ischemia and procoagulant states. As evidenced in this report, we successfully F I G U R E 1 A, Contrast-enhanced computed tomography (CT) scan of brain demonstrating left-sided ischemic stroke. B, CT scan of chest demonstrating a large pulmonary embolus extending into the main pulmonary arteries. C, Trans-esophageal echocardiogram demonstrating thrombus formation (red arrows) within the right ventricle. D, Multiple thrombi retrieved from pulmonary artery intraoperatively employed various ECMO strategies, even in the challenging context of contemporaneous acute ischemic stroke, which could risk hemorrhagic conversion, central pulmonary embolism, kidney injury and upper limb ischemia, following high-risk pulmonary endarterectomy in an unstable patient. We've followed the standards of anticoagulation for circulatory support patients. 7 Thus, the judicious use of ECMO in carefully selected patient cohorts in experienced centers may be of great benefit to, and achieve favorable clinical outcomes in patients developing cardiorespiratory complications during the current COVID-19 era. ECMO should be perceived as an accessible and highly valuable tool in the clinician's armamentarium, rather than a "last resort" option in apparently futile cases. In conclusion, we report a successful outcome in a young patient who underwent short-term MCS and high-risk cardiothoracic surgery for the treatment of acute right heart failure with severe pulmonary embolism and large-vessel embolic stroke as a complication of COVID-19 infection. Short-term MCS with different cannulation strategies may represent a viable treatment modality for cardiovascular complications with venous and arterial thromboembolism in patients with COVID-19 infection. Clinical features of patients infected with 2019 novel coronavirus in Wuhan Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China Initial ELSO guidance document: ECMO for COVID-19 patients with severe cardiopulmonary failure Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Large-vessel stroke as a presenting feature of COVID-19 in the young The role of extracorporeal membrane oxygenation circulatory support in the 'crash and burn' patient: from implantation to weaning Mechanical circulatory support for cardiovascular complications in a young COVID-19 patient The authors declare that there are no conflict of interests. Informed consent was obtained from the patient. Local institutional ethical processes were followed.